Scarica l'app Stockscreener
0.0918
0.65%
-0.0006
Lyra Therapeutics Inc Borsa (LYRA) Ultime notizie
Petri Dish: Thermo Fisher’s new partner; Waters buys California company - The Business Journals
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
US Stocks Likely To Open Lower After S&P 500's Six-Day Streak: 'Quick Recoveries Tend To See Stocks Rally More Over The Next 3-12 Months,' Says ExpertASP Isotopes (NASDAQ:ASPI) - Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Lyra Therapeutics Announces Reverse Stock Split Decision - TipRanks
Lyra Therapeutics Reports Q1 2025 Financial Results - TipRanks
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates - MSN
JPMorgan Chase & Co. Has $32,000 Stake in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
Lyra Therapeutics to Present 52-Week Extension Stage Results for Enlighten 1 Phase 3 Study for Lyr-210 for the Treatment of Chronic Rhinosinusitis At Cosm 2025 - marketscreener.com
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
Lyra Therapeutics Reports Positive Safety and Efficacy Results for LYR-210 in Phase 3 Extension Study for Chronic Rhinosinusitis - Nasdaq
Lyra Therapeutics to Present 52-week Extension Stage - GlobeNewswire
Lyra Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 - GlobeNewswire Inc.
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Receives $1.25 Consensus Target Price from Analysts - Defense World
Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Lyra Therapeutics Nears Critical Phase 3 Results for Revolutionary CRS Treatment as Q1 Losses Narrow 62% - Stock Titan
JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Geode Capital Management LLC Has $183,000 Stock Position in Lyra Therapeutics, Inc. (NASDAQ:LYRA) - Defense World
JPMorgan Chase & Co. Sells 89,034 Shares of Angi Inc. (NASDAQ:ANGI) - Defense World
Lyra Therapeutics Inc (LYRA) expanding its growth trajectory ahead - Sete News
Financial Fitness Check: Examining B. Riley Financial Inc (RILY)’s Key Ratios - DWinneX
Rhinitis Pipeline 2025: Groundbreaking Clinical Advancements - openPR.com
Keeping an Eye on Lyra Therapeutics Inc (LYRA) After Insider Trading Activity - knoxdaily.com
Lyra Therapeutics Inc (LYRA) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
What was Lyra Therapeutics Inc (LYRA)’s performance in the last session? - uspostnews.com
Recent Insider Activity Could Benefit Schrodinger Inc (SDGR) - knoxdaily.com
Layoff Tracker: Ono Cuts 83 Employees in Massachusetts - BioSpace
Lyra Therapeutics (LYRA) to Release Quarterly Earnings on Tuesday - The AM Reporter
Lyra Therapeutics (LYRA) Expected to Announce Quarterly Earnings on Tuesday - American Banking and Market News
iCoreConnect Inc [ICCT] Shares Fall Approximately -87.86% Over the Year - knoxdaily.com
Lyra Therapeutics Inc [LYRA] Shares Rise 7.02 % on Thursday - knoxdaily.com
QBTS Stock Sees Surge of Approximately 14.13% in Last Five Days - knoxdaily.com
Deckers Outdoor Corp [DECK] Records 200-Day SMA of $160.33 - knoxdaily.com
Shopify Inc [SHOP] Records 50-Day SMA of $99.94 - knoxdaily.com
Analysts Say Lyra Therapeutics Inc (NASDAQ:LYRA) Can Really Get To 0.5 In 12 Months - Marketing Sentinel
An Analysis of Lyra Therapeutics Inc (LYRA)’s Potential Price Growth - knoxdaily.com
Take off with Lyra Therapeutics Inc (LYRA): Get ready for trading - Sete News
Is Lyra Therapeutics Inc (LYRA) worth investing in despite its undervalued state? - uspostnews.com
Brokerages Set Lyra Therapeutics, Inc. (NASDAQ:LYRA) Target Price at $1.25 - Defense World
Lyra Therapeutics stock hits 52-week low at $0.1 By Investing.com - Investing.com Australia
Lyra Therapeutics stock hits 52-week low at $0.1 - Investing.com
TCBI Stock Sees Decline of Approximately -2.19% in Last Five Days - knoxdaily.com
Technical analysis of Lyra Therapeutics Inc (LYRA) stock chart patterns - uspostnews.com
Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline By Investing.com - Investing.com South Africa
Lyra Therapeutics stock hits 52-week low at $0.14 amid sharp decline - Investing.com Australia
PTCT Stock Sees Decline of Approximately -2.93% in Last Five Days - knoxdaily.com
Lyra Therapeutics Inc (LYRA) deserves deeper analysis - uspostnews.com
A Closer Look at Lyra Therapeutics Inc (LYRA) Stock Gains - investchronicle.com
Lyra Therapeutics stock plunges to 52-week low of $0.16 By Investing.com - Investing.com Australia
17.27%
1.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):